While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > ORGANIZATION
ORGANIZATION
- MHLW, JPWA Hold Public-Private Dialogue on Distribution Improvement
January 30, 2012
- JPWA Board of Directors Approve By-Category Talks to Be Common Understanding
January 27, 2012
- JPA Supports Ban on “Dispensing Point” Services at Pharmacies
January 26, 2012
- JSMI to Seek Expansions of OTCs by Appealing Preventive Effects in 2012
January 24, 2012
- JPMA to Focus on Thorough Enforcement of Compliance in Next Fiscal Year
January 20, 2012
- JPMA to Discuss State of Long-Listed Products Over a Year Ahead of FY2014 Revision
January 19, 2012
- JPMA to Set Transparency Guideline for Relationships with Patient Organizations, Disclose Information from FY2013
January 19, 2012
- JPWA, NPhA Hold Talks for Distribution Improvement
January 18, 2012
- FPMAJ Detects Radioactive Substances in 2 Crude Raw Material Samples
January 17, 2012
- JGA President Sawai Says Members United to Provide Stable Drug Supplies to Meet Boosted Demand
January 13, 2012
- JPWA President Bessho Expresses Resolve for Distribution Improvement
January 12, 2012
- PMAT President Matsuda Says Permanent Introduction of Premium is Priority Issue
January 10, 2012
- FPMAJ Chairman Pledges Further Efforts for Permanent Introduction of Premium, Caution Towards Additional Price Cuts Becoming Rule
January 5, 2012
- New Year’s Remarks: We wish each of our stakeholders a very Happy and Healthy New Year 2012.
January 5, 2012
- 2012 New Year’s Message: The Ultimate Winner of the Medical Policy Changes is the Patient
January 5, 2012
- New Year’s Message: On behalf of the JPMA, I would like to express our best wishes for a Happy New Year as we see the start of 2012.
January 5, 2012
- JGA to Push for Changing Brand-Based Product Names to Generic Names
December 28, 2011
- JGA President Sawai Says Additional Price Cuts for Generics “In No Way Acceptable”
December 27, 2011
- FPMAJ, JPMA “Truly Regret” Additional Price Cuts for Long-Listed, Generic Drugs
December 27, 2011
- JPMA's Kawabe Says Additional Price Cut for Long-Listed Products is “Not a Rule”
December 22, 2011
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…